score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Inferential			Mutational Signature	COSMIC Signature 3		0.435						Investigate Actionability - High	Platinum	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683												0				COSMIC Signature 3 (44%)		TP_2009		
Investigate Actionability - Low	Clinical trial	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.SD884fs	0.2167	120.0	0.0	0.0		Investigate Actionability - Low	Olaparib	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.SD884fs (Frameshift)	0.0	TP_2009	TP_2009-Tumor	TP_2009-Normal
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.QATSAFQTQ631fs	0.0946	74.0	0.0	0.0																			0	0.0	0.0	0.0	RB1 p.QATSAFQTQ631fs (Frameshift)		TP_2009	TP_2009-Tumor	TP_2009-Normal
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.PPA66del (Deletion)																							0				Supporting variants: MSH3 p.PPA66del (Deletion)		TP_2009		
Biologically Relevant				Mutational Signature	COSMIC Signature 6		0.243																							0				COSMIC Signature 6 (24%)		TP_2009		
